This page lists 4 EU acts most likely to matter for Pharmaceuticals & Life Sciences, matched from official EUR-Lex legislation titles and linked to sourced explainers. Source: EUR-Lex and European Parliament procedure records. Methodology
EU regulation for Pharmaceuticals & Life Sciences
Pharmaceutical and life-sciences companies face EU rules on medicines authorisation, clinical trials and supply-chain integrity across the single market. These are the EU acts most likely to apply.
The EU laws most likely to apply
- Regulation (EU) 2023/1182 on specific rules relating to medicinal products for human use intended to be placed on the market in Northern Ireland32023R1182
- Regulation (EU) 2022/839 laying down transitional rules for the packaging and labelling of veterinary medicinal products authorised or registered in accordance with Directive 2001/82/EC or Regulation (EC) No 726/200432022R0839
- Regulation (EU) 2022/123 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices32022R0123
- Regulation (EU) 2020/1043 on the conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease (COVID-19)32020R1043
What’s coming for your company specifically?
Describe your business in a sentence — Lex scans the EU files heading your way, grounded and cited, free.
Scan your regulatory exposure →Each act links to its plain-language explainer; full texts and procedure files are cited there. Data © European Union (Decision 2011/833/EU). Methodology.